Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27.2M
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
8.18M
-
Shares change
-
+8.18M
-
Total reported value, excl. options
-
$52.7M
-
Value change
-
+$52.7M
-
Put/Call ratio
-
0.09
-
Number of buys
-
37
-
Price
-
$6.44
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q3 2022
40 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q3 2022.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.18M shares
of 27.2M outstanding shares and own 30.08% of the company stock.
Largest 10 shareholders include Artal Group S.A. (1.46M shares), Bain Capital Life Sciences Investors, LLC (1.08M shares), Flagship Pioneering Inc. (994K shares), Avidity Partners Management LP (900K shares), Ally Bridge Group (NY) LLC (868K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (722K shares), VANGUARD GROUP INC (488K shares), CVI Holdings, LLC (426K shares), DAFNA Capital Management LLC (266K shares), and FMR LLC (252K shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.